Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes
In the SYNCHRONIZE-2 trial, which met its co-primary endpoints, participants achieved significant body weight reduction of up to 13.1% versus 3.1% in the placebo arm, after 76 weeks of treatment with survodutide in people with type 2 diabetes, a population in which weight loss is typically more challenging.1 Detailed results from the Phase III trial […]
New study data presented at the 2026 EASD annual meeting reveals that a combination of Eli Lilly's experimental drugs eloralintide and tirzepatide (TZP) can lead to significant weight loss and improved blood sugar control in patients with obesity and type 2 diabetes. The 48-week trial involving 367 adults found that the highest dose (Elora 9 mg + TZP 15 mg) resulted in an average 23.3% body weight reduction (24.6 kg or 54.2 pounds) and a 2.9% decrease in HbA1c levels.
The most frequent side effects were mild gastrointestinal issues that occurred more often during combination therapy than with either drug alone.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
